Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases

Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases is a phase 2/3, randomised interventional study registered as NCT07321847 by Immunophotonics, Inc., with a registry enrolment figure of 717 participants, started 2026-05 and due to reach its primary completion in 2033-12. Interventions recorded: 1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water; 1.0% IP-001 for Injection, a 1 mg/mL solution of IP-001 in water.; Microwave (thermal) tumor ablation. Conditions listed: Colorectal Cancer (CRC); Colon Cancer Liver Metastases; Rectal Cancer; Rectal Cancer With Liver Metastases; Colorectal Liver Metastasis (CRLM). Primary outcome: To compare the efficacy of IP-001 following standard-of-care (SOC) complete hepatic tumor ablation vs SOC complete hepatic tumor ablation alone in prolonging progression-free survival. Colorectal eligibility wording from the registry: "No residual primary colorectal tumor at Treatment Day 1 or plans to have the primary tumor excised within 4-12 weeks following Treatment Day 1". No results are recorded here; the registry entry is the source.